HARROW HEALTH, INC. IMMY Cash Flow

Harrow health, inc. (IMMY)

CashFlow / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
CASH FLOWS FROM OPERATING ACTIVITIES
Total net (loss) income including noncontrolling interests
-12,923	2,592	-11,630	-2,420	11,333	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net income (loss) attributable to Harrow Health, Inc.
-	-	-	-	-	-	-	-	-3,513	-2,771	-5,692	1,484	-5,006	-6,102	-3,850	-4,639	-4,496	-5,124	-3,952	-3,730	-3,093	-2,745	-2,452	-2,596	-2,325	-1,882	-2,077	-2,218	-1,465	-1,453	-1,245	-1,305	-1,379	-271	-85	-164	-432
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Depreciation and amortization of property, plant and equipment
448	571	397	578	390	385	423	401	399	360	382	314	345	356	348	268	83	69	84	58	44	17	9	8	3	-	-	-	-	-	-	-	-	-	-	-	-
Estimated fair value of contributed services
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0
Gain on forgiveness of liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	60	0	0	0
Amortization of prepaid consulting fees
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0
Depreciation and amortization of furniture and equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	1	1	0	0	0	0	0	0	0	0	0
Amortization of intangible assets
45	34	50	63	62	59	59	57	60	92	91	91	90	89	-93	264	91	91	88	94	82	17	13	18	0	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of operating lease right-of-use assets
169	-	-	-	130	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash gain on contingent acquisition obligation
-	-	-	-	-	-	-	-	-	-	-	-	28	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of debt issuance costs and discount
160	118	131	128	135	147	152	155	159	166	180	296	336	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred income taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-111	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of debt issuance costs and discount
-	-	-	-	-	-	-	-	-	-	-	-	-	141	303	264	262	106	105	70	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Debt extinguishment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-189	-1,006	0	0	0	0
Paid-in-kind interest added to principal of note payable
-	-	-	-	-	-	-	-	-	-	-	-	-	50	52	50	51	51	51	28	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Investment loss
-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on sale and disposal of assets
-	-135	-3,937	-80	4	-	-	-	-	-139	-42	-158	-15	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stock-based payment of consulting services
-	84	75	0	75	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash gain on contingent acquisition obligations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	31	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of derivative liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	113	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash interest on notes payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	3	21	18	18	18	18
Stock-based compensation
533	381	328	367	713	536	591	608	751	678	648	667	950	684	764	1,161	1,064	1,124	956	703	658	664	554	709	688	808	878	1,037	410	654	654	729	118	42	36	43	68
Payments made on behalf of Company by related party
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Changes in assets and liabilities:
Accounts receivable
20	-806	592	29	280	182	371	-114	-55	-1,096	-231	-180	115	-81	1,080	979	103	139	122	143	-44	13	-13	21	2	0	0	0	0	-	-	-	-	-	-	-	-
Inventories
688	858	595	264	554	-690	308	176	-209	-125	542	201	203	-61	461	208	-179	-291	417	82	106	22	178	-40	0	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid consulting costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0
Prepaid expenses and other current assets
8	-57	-36	-257	821	-277	132	131	137	-229	157	-189	-13	-298	747	-290	-7	101	249	98	97	-95	11	171	45	-241	536	-136	-142	14	-30	17	-48	59	-3	-8	-1
Accounts payable and accrued expenses
-337	-379	891	672	158	212	1,268	779	106	-151	691	-558	364	-133	78	574	996	183	724	17	104	-27	54	173	145	-469	-54	218	65	170	-55	79	38	-	-	-	-
Accounts payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	87
Accrued Phase 3 expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0
Accrued payroll and related liabilities
333	205	336	484	-1,191	556	-69	754	-167	-81	-191	501	-658	345	161	465	-533	104	389	-145	105	-38	201	319	-140	63	92	90	72	-0	7	2	9	-58	0	10	38
Deferred revenue and customer deposits
3	9	-176	-135	240	21	64	-39	44	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue and customer deposits
-	-	-	-	-	-	-	-	-	-	0	0	-83	37	28	-24	-15	44	-52	56	15	-1	2	-12	0	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	-100	0	0	20	0
NET CASH USED IN OPERATING ACTIVITIES
-550	1,652	-70	844	-1,476	-36	323	1,365	-965	-294	-2,224	-2,305	-3,980	-2,238	-3,909	-2,767	-2,301	-3,301	-2,395	-3,172	-2,275	-2,053	-1,795	-1,533	-1,676	-1,238	-1,137	-1,004	-1,057	-613	-669	-282	-334	25	-30	-65	-220
CASH FLOWS FROM INVESTING ACTIVITIES
Repayment of note receivable
-	-	-	-	-	0	0	0	4	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds on sale and disposal of assets
-	-	-	-	4	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Repayment on note receivable
-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of restricted short-term investments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-50	0	0	0	0	-	-	-	-
Purchase of Park Compounding, net of cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	3,005	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of Pharmacy Creations, LLC, net of cash and advances
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-595	-41	-	-	-	-	-	-	-	-	-	-	-	-
Investment in patent and trademark assets
53	90	59	105	115	152	129	78	76	68	41	77	66	67	50	79	56	56	129	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash advances to Pharmacy Creations, LLC
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Purchases of property, plant and equipment
220	879	24	352	213	700	518	358	192	184	266	172	150	347	795	3,378	2,367	-1,699	496	180	28	82	77	5	10	9	5	3	1	0	0	0	14	0	0	0	0
NET CASH USED IN INVESTING ACTIVITIES
-273	-969	-79	-461	-324	-852	-647	-436	-264	-249	-197	-299	-216	-164	-1,145	-3,557	-2,423	-871	-1,046	-180	-3,033	-82	-77	-700	-51	-9	-5	-3	-51	-0	0	-0	-14	0	0	0	0
CASH FLOWS FROM FINANCING ACTIVITIES
Payments on finance lease obligations
2	-1	369	190	185	179	175	170	167	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments on capital lease obligations
-	-	-	-	-	-	-	-	-	162	159	153	152	148	105	7	7	7	7	4	7	6	3	1	0	-	-	-	-	-	-	-	-	-	-	-	-
Net proceeds from public equity offering
-	-	-	-	-	-	-	-	-	0	0	-1	2,941	0	0	0	11,088	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net proceeds from private placement equity offering
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Cancelled common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-0	0	0	-	-	-	-	-	-	-	-
Payments on Park deferred acquisition obligation
-	-	-	-	-	0	0	0	53	105	0	51	50	50	48	49	48	48	47	40	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Principal payments on note payable
-	0	0	0	750	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from note payable, net of issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-38	0	9,303	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from convertible note payable, net of issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	2,772	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net proceeds from ATM sales of common stock
-	-	-	-	-	0	1	519	122	962	162	0	0	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	10,052	-342	3,943	7,903	0	-	-	-	-
Payment for settlement of shares in connection with reverse stock split
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-
Proceeds from issuance of notes payable to a related party
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	150	300	300	0	0	0
Proceeds received in connection with debt modification
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	50	0	0	0	0
Proceeds from issuance of preferred stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	100	0	0	0
Proceeds from notes payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0
Preferred stock deemed dividend paid at conversion
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-200	0	-	-	-	-
Cash advances to and from related parties
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	254	0	0	0
Cash advances from related party
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	27	0	0
Repayment of advances from related party
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	281	0	0	0
Capital contributions
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0
Net proceeds from exercise of warrants
-	-	-	17	162	-	-	-	-	-	-	-	-	-143	0	0	55	-10	0	1,171	77	1	137	135	349	0	0	0	0	-	-	0	0	0	0	0	0
Payments for deferred offering costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-75	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NET CASH USED IN FINANCING ACTIVITIES
-2	635	-413	-455	-773	1,411	2,469	349	-98	695	2,123	-627	2,739	8,893	1,975	-56	13,860	301	-54	10,505	-5	-18	134	134	349	0	0	0	10,052	-341	3,943	7,853	350	118	27	0	0
NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH
-825	1,318	-562	-72	-2,573	523	2,145	1,278	-1,327	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH
-	-	-	-	-	-	-	-	-	-	-298	-3,231	-1,457	6,491	-3,079	-6,380	9,136	-3,871	-3,495	7,153	-5,313	-2,153	-1,738	-2,099	-1,378	-1,248	-1,142	-1,008	8,943	-955	3,273	7,570	0	144	-3	-65	-220
RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH
Cash and cash equivalents
3,924	1,318	-562	-72	4,065	523	2,145	1,278	2,692	152	-298	146	4,019	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Restricted cash
200	0	0	0	200	0	0	0	200	0	0	0	200	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for income taxes
-	-	-	-	-	0	0	2	2	0	9	0	0	0	0	0	9	0	0	0	1	0	0	0	1	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for interest
408	421	493	586	467	1,091	0	523	483	498	144	473	428	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Right-of-use asset obtained in exchange for lease obligation
41	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Changes in accrued property and equipment purchases
-	-	-	-	5	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Acquisition of property, plant and equipment with finance lease obligations
-	-	-	0	40	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	368	325	291	223	346	66	2	1	1	2	0	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for income taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	0	0	0	1	-	-	-	-
Fair value of embedded conversion feature recorded as debt discount and derivative liability
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	2,322	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Reclassification of the fair value of the embedded conversion feature derivative liability to additional paid-in capital upon closing of the public equity offering
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	2,646	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Reclassification of the fair value of the LSAF warrant from additional paid-in capital to derivative liability
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	675	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Reclassification of the fair value of the LSAF warrant derivative liability to additional paid-in capital upon closing of the public equity offering
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	464	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Issuance of common stock and fair value of deferred acquisition obligations related to the purchase of Park Compounding
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	50	966	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Issuance of stock and stock options for consulting services included in accounts payable and accrued expenses
-	-	-	-	-	-	0	0	108	-	0	0	0	0	0	0	23	0	0	0	39	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of property, plant and equipment included in accounts payable and accrued expenses
-	-	-	-	-	-	-	-	-	-	-	-	18	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Issuance of and adjustment to common stock and warrants to consulting firms for prepaid consulting fees
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0
Conversion of related party accounts payable into common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	56	0	0	0	0
Conversion of notes payable and accrued interest into common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	762	1,142	-	0	0	0
Forgiveness of notes payable and accrued interest to shareholders
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Forgiveness of notes payable and accrued interest to shareholders
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0
Conversion of advances to notes payable to shareholders
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0
Accretion of preferred stock discount
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-100	100	-100	0	0	0
Related party acquisition of Phase 3 liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-56	56	56	0	0	0
Conversion of preferred stock into common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	1	0	-	-	-	-
Reclassification of deferred offering costs in connection with equity offering
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	596	0	0	0	0	-	-	-	-
Issuance of common stock for consulting services included in accounts payable and accrued expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-180	180	139	0	-	-	-	-	-	-	-	-
Purchase of property, plant and equipment included in accounts payable and accrued expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-41	-155	-871	1,148	1,275	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Eton Pharmaceuticals [Member]
Investment (loss) gain, net
-10,850	-	-	-	6,580	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Investment gain from and equity in net loss
-	-	-	-	-	-	-	-1,146	-1,069	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Surface Pharmaceuticals [Member]
Investment (loss) gain, net
-339	-	-	-	-243	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Melt Pharmaceuticals [Member]
Investment (loss) gain, net
-546	-	-	-	5,525	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-